Affymax to receive development milestone payment from Takeda Pharmaceutical Business Review Peginesatide, indicated to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis, was discovered by Affymax. If approved, peginesatide will be co-marketed by Affymax and Takeda in the US. Takeda has commercialization ... Takeda Announces Acceptance of European Marketing Authorisation Application ... Affymax to Receive $5 Million Milestone Payment for Acceptance of European ... Search in our News Channels |
